1. Home
  2. CRSP vs THG Comparison

CRSP vs THG Comparison

Compare CRSP & THG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$50.24

Market Cap

5.1B

Sector

Health Care

ML Signal

HOLD

Logo Hanover Insurance Group Inc

THG

Hanover Insurance Group Inc

HOLD

Current Price

$174.23

Market Cap

6.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
THG
Founded
2013
1852
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
6.0B
IPO Year
2016
1995

Fundamental Metrics

Financial Performance
Metric
CRSP
THG
Price
$50.24
$174.23
Analyst Decision
Buy
Buy
Analyst Count
20
6
Target Price
$71.95
$196.67
AVG Volume (30 Days)
1.8M
433.6K
Earning Date
02-11-2026
02-03-2026
Dividend Yield
N/A
2.18%
EPS Growth
N/A
58.62
EPS
N/A
18.56
Revenue
$38,337,000.00
$6,594,400,000.00
Revenue This Year
N/A
$4.23
Revenue Next Year
$1,376.73
$5.18
P/E Ratio
N/A
$9.38
Revenue Growth
N/A
5.72
52 Week Low
$30.04
$147.76
52 Week High
$78.48
$188.18

Technical Indicators

Market Signals
Indicator
CRSP
THG
Relative Strength Index (RSI) 40.76 48.59
Support Level $49.10 $171.10
Resistance Level $53.00 $174.11
Average True Range (ATR) 3.12 3.21
MACD -0.48 0.73
Stochastic Oscillator 12.40 44.86

Price Performance

Historical Comparison
CRSP
THG

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About THG Hanover Insurance Group Inc

The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business internationally through a wholly owned subsidiary, Chaucer Holdings Limited, domiciled in the United Kingdom. The company conducts business operations through four operating segments: Core Commercial, Specialty, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.

Share on Social Networks: